Many of today’s leading drugs are directly injected into the patient’s body, which is why the global injectable drug delivery market is anticipated to grow at a rate of 8.67 percent through 2027. This growth is reflective of Dr. Reddy’s injectable portfolio for medical specialties. The team at Dr. Reddy’s has made a concerted effort to ensure that their injectable delivery system exceeds patient need and improves the injectable experience.

Dr. Reddy’s Laboratories have honed its capabilities in the injectable and inhalation space through world-class capabilities and best-in-class teams. Their work has resulted in a strong track record in developing, marketing, and distributing generic injectables. These credentials and operations contribute to the accessibility and affordability of medications.

Dr. Reddy’s most recently launched injectable is Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection 4 mcg/mL, approved by the FDA. This product is a strong addition to the injectable offerings in the U.S. market and reflects a commitment to act with speed to find innovative solutions and accelerate access to much-needed medicines.